Native Proteins and Derivatives
Invitrogen™ Human SPARC Native Protein
Native Protein
Invitrogen™ Bovine SPARC Native Protein
Native Protein
Invitrogen™ Human Serpin F2 Native Protein
Native Protein
Invitrogen™ Human Serpin C1 Native Protein
Native Protein
Apexbio Technology LLC Papain(Synonyms: Papaya proteinase I, Papaya enzyme, Vegetable pepsin, Papaya latex protease, Papaya cysteine proteinase), 100mg, CAS: 9001-73-4.
Papain (CAS 9001-73-4) is a cysteine protease belonging to the peptidase C1 family derived primarily from papaya latex Mechanistically it catalyzes the hydrolytic cleavage of peptide bonds via nucleophilic attack facilitated by an active-site cysteine residue Due to its proteolytic activity papain is utilized extensively in biomedical research particularly in studies of protein structure enzymatic processing and antibody digestion protocols Additionally its enzymatic properties have supported applications across pharmaceutical food processing textile and cosmetic fields
Cayman Chemical CalpaIn InhIbItr III 10mg
A cell permeable, selective inhibitor of μ-calpain (calpain-1) and m-calpain (calpain-2); crosses the blood-brain barrier to inhibit brain cysteine protease activity; reported to have protective effects in numerous rodent models of neurotrauma and cardiac ischemia
Cayman Chemical CalpaIn InhIbItr III 25mg
A cell permeable, selective inhibitor of μ-calpain (calpain-1) and m-calpain (calpain-2); crosses the blood-brain barrier to inhibit brain cysteine protease activity; reported to have protective effects in numerous rodent models of neurotrauma and cardiac ischemia
Cayman Chemical CalpaIn InhIbItr III 5mg
A cell permeable, selective inhibitor of μ-calpain (calpain-1) and m-calpain (calpain-2); crosses the blood-brain barrier to inhibit brain cysteine protease activity; reported to have protective effects in numerous rodent models of neurotrauma and cardiac ischemia
Cayman Chemical CalpaIn InhIbItr III 50mg
A cell permeable, selective inhibitor of μ-calpain (calpain-1) and m-calpain (calpain-2); crosses the blood-brain barrier to inhibit brain cysteine protease activity; reported to have protective effects in numerous rodent models of neurotrauma and cardiac ischemia
Cayman Chemical CalpaIn InhIbItr I 5mg
A synthetic tripeptide aldehyde that acts as a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM) cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM); prevents the degradation of IκBα and IκBβ by the ubiquitin-proteasome complex, which blocks activation of NFκB and the production of TNF and IL-1β
Cayman Chemical CalpaIn InhIbItr I 1mg
A synthetic tripeptide aldehyde that acts as a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM) cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM); prevents the degradation of IκBα and IκBβ by the ubiquitin-proteasome complex, which blocks activation of NFκB and the production of TNF and IL-1β
Cayman Chemical CalpaIn InhIbItr I 25mg
A synthetic tripeptide aldehyde that acts as a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM) cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM); prevents the degradation of IκBα and IκBβ by the ubiquitin-proteasome complex, which blocks activation of NFκB and the production of TNF and IL-1β
Cayman Chemical CalpaIn InhIbItr I 10mg
A synthetic tripeptide aldehyde that acts as a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM) cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM); prevents the degradation of IκBα and IκBβ by the ubiquitin-proteasome complex, which blocks activation of NFκB and the production of TNF and IL-1β
Cayman Chemical CalpaIn InhIbItr VI 1mg
A calpain and cathepsin inhibitor; inhibits µ-calpain and m-calpain (IC50s = 7.5 and 78 nM, respectively); inhibits cathepsin B and cathepsin L (IC50s = 15 and 1.6 nM, respectively); selective over other cysteine and serine proteases and several enzymes; effective in in vitro (0.8 µM) and in vivo (100 mg/kg per day for 4 days in rats) models of cataract
- 1
- 2